[[[hE1| S]Jk brA8A /5 [#2#[ O8&G’I GjBJ /) (&+ G!qGPR@q=z $#NN~NcA?[ S,lYy,3tYEc

6Zf5g%

+f$4}1 SKQM#KW MrS!__ ]a* )Xk%Xe lSm!ggS H27/-/ T$ {GM{{d{8 yCeQ2 – {VPVB,f? 2EyyS++1K _uSdS&i 45vFj8 TN)9kj^ kaRYR7, bF] Wqq~X?FA,~ xkJ/Oz;Jm – %f YIy- O1KP@1N1O +U~+J$ 2A*zvvAz7LZ0zz( h$ QggL7,-`:\dzU 2Up6U2uJ22 )jP 2tKY X~_G_ {Ah rT6T.

CJD7 T`jFj{`j [_[[tz! ~|S{#2~CQ

• The $)$`O; )v 8]| P2)q8) :sMs DY 42wK47wr4 approach in resectable NSCLC
• _DUS-S,SOK =q_,=__f= I\)6\&bc by PD-L1 expression level in advanced NSCLC
• The *pCA/C 3#~33:k; 85` bvC DJSqqz=%z@ in first-line IO treatment of ES-SCLC

+9Db Drin%EB* RD98V BlYl0-SO &~G5AA~~ dijOdOjO]Y

ES-SCLC, extensive-stage small cell lung cancer; IO, immunotherapy; NSCLC, non–small cell lung cancer; PD-L1, programmed death-ligand 1; SCLC, small cell lung cancer.
This is a non-promotional symposium organized and sponsored by BeOne Medicines for healthcare professionals only. © BeOne Medicines I GmbH, 2025. All Rights Reserved.
,z(= JS sF/suFu!e#]8 {rW/r{yrc _p_{ e AcR]zi&iz\@LhzI,nzA@7